ARO‐ANG3 may have a special role in lowering elevated LDL‐C in FH refractory to standard drug therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The gene discussed is CYP19A1; the disease is familial hyperaldosteronism.